TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment
Go back to TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment| TG THERAP (NASDAQ: TGTX) | Delayed: 56.87 +0.40 (0.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.47 | 52 Week High | $14.87 | |||
| Open | $56.98 | 52 Week Low | $4.90 | |||
| Day High | $57.73 | P/E | N/A | |||
| Day Low | $56.18 | EPS | $-0.67 | |||
| Volume | 5,168,987 | |||||
